SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
14.26
30
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Wall Street
Price Targets
1SXP Price Targets Summary
SCHOTT Pharma AG & Co KgaA
According to Wall Street analysts, the average 1-year price target for
1SXP
is 21.23 EUR
with a low forecast of 14.14 EUR and a high forecast of 27.3 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is 1SXP's stock price target?
Price Target
21.23
EUR
According to Wall Street analysts, the average 1-year price target for
1SXP
is 21.23 EUR
with a low forecast of 14.14 EUR and a high forecast of 27.3 EUR.
What is SCHOTT Pharma AG & Co KgaA's Revenue forecast?
Projected CAGR
7%
For the last 4 years the
compound annual growth rate for
SCHOTT Pharma AG & Co KgaA's revenue is
11%.
The projected
CAGR
for the next 3 years is
7%.
What is SCHOTT Pharma AG & Co KgaA's Operating Income forecast?
Projected CAGR
12%
For the last 4 years the
compound annual growth rate for
SCHOTT Pharma AG & Co KgaA's operating income is
13%.
The projected
CAGR
for the next 3 years is
12%.
What is SCHOTT Pharma AG & Co KgaA's Net Income forecast?
Projected CAGR
12%
For the last 4 years the
compound annual growth rate for
SCHOTT Pharma AG & Co KgaA's net income is
10%.
The projected
CAGR
for the next 3 years is
12%.